In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

Xenobiotica

Volumn 41, Issue 5, 2011, Pages 400-408

  Huang, Liyue ^a   Be, Xuhai ^a   Berry, Loren ^a   Moore, Earl ^a   Janosky, Brett ^a   Wells, Mary ^a   Pan, Wei Jian ^a   Zhao, Zhiyang ^a   Lin, Min Hwa Jasmine ^a  

^a AMGEN INC   (United States)

Author keywords

allometric scaling; AMG 900; Aurora kinase inhibitor; food effect; MDR1; pharmacokinetics

Indexed keywords

AMG 900; AURORA KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE; SOLID TUMOR;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CELL LINE; FASTING; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PHTHALAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 79954461866     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.548534     Document Type: Article

References (30)

1. Andrews PD. (2005). Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005-5015. (Pubitemid 41129079)
2. Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227. (Pubitemid 12044187)
3. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA. (2008). Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36:1357-1364. (Pubitemid 351929320)
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. (2004). Aurora-A/ STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25:1631-1639.
6. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. (2008). Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639-1648. (Pubitemid 351471713)
7. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ. (2003). Activation and overexpression of centrosome kinase BTAK/aurora-A in human ovarian cancer. Clin Cancer Res 9:1420-1426. (Pubitemid 36418396)
8. Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, Lin MH. (2010). Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 38:223-231.
9. Jeng YM, Peng SY, Lin CY, Hsu HC. (2004). Overexpression and amplification of aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065-2071.
10. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M. (1999). Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160-1162. (Pubitemid 29330556)
11. Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Höög C, van Duin M, Gossen JA, Sassone-Corsi P. (2007). Differential functions of the aurora-B and aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 21:726-739.
12. Kimura M, Matsuda Y, Yoshioka T, Okano Y. (1999). Cell cycledependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274:7334-7340.
13. Kitzen JJ, de Jonge MJ, Verweij J. (2010). Aurora kinase inhibitors. Crit Rev Oncol Hematol 73:99-110.
14. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590. (Pubitemid 27203406)
15. Lentz KA. (2008). Current methods for predicting human food effect. AAPS J 10:282-288.
16. Mahmood I. (1998). Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions. J Pharm Pharmacol 50:493-499. (Pubitemid 28241135)
17. Mahmood I. (2005). Interspecies Pharmacokinetic Scaling. Rockville, MD: Pine House Publishers.
18. Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
19. McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8: 463-479. (Pubitemid 47603410)
20. Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
21. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. (2009). Predicting pharmacokinetics of drugs using physiologically based modeling- application to food effects. AAPS J 11:45-53.
22. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault, Patel VF, Geuns- Meyer S, Radinsky R, Kendall RL. (2010). Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 70:9846-9854.
23. Pollard JR, Mortimore M. (2009). Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 52:2629-2651.
24. Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
25. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524. (Pubitemid 26187339)
26. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204-3212.
27. Singh BN, Malhotra BK. (2004). Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43:1127-1156. (Pubitemid 40013180)
28. Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M, Liu Z, Wang M, Guo L, Lu S, Wu M, Zhan Q. (2004). Overexpression of aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10:7304-7310. (Pubitemid 39487719)
29. Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
30. Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250-254. (Pubitemid 40175478)